Loading…
Loading…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI PR Newswire
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. ("Sanara" or the "Company") (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Sanara MedTech delivered a strong Q1 2026, with 19% revenue growth, 93%+ gross margins, and its first GAAP profit in years. SMTI's strategic discontinuation of the THP segment has materially improved profitability, allowing management to focus on the high-return Surgical business. Operating margins now exceed 10%, and guidance for 2026 revenue is $116M–$121M, supporting a Buy rating despite the recent 30% stock rally.
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanara MedTech, Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sanara MedTech Inc. (SMTI) Q1 2026 Earnings Call Transcript
Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0. 04 Per Fully Diluted Share for the Quarter FORT WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," "Sanara MedTech," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the first quarter ended March 31, 2026.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for SMTI and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.